Trial · NCT07879924

Dual Neuromodulation for Depression: Boosting TMS With tES

NCT07879924, Not applicable, Not yet recruiting, Mersey Care NHS Trust

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dual Neuromodulation for Depression: Boosting TMS With tES. Trials, record NCT07879924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879924

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dual Neuromodulation for Depression: Boosting TMS With tES
NCT number: NCT07879924
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 60 participants, estimated
Lead sponsor: Mersey Care NHS Trust
Conditions: Depression - Major Depressive Disorder
Interventions: Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
First posted: 2026-10-19
Last updated: 2026-10-19

Source ClinicalTrials.gov

Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in emotional bias (Cambridge Neuropsychological Test Automated Battery (CANTAB) Emotional Bias task)	First measured at the baseline session (28 days within the first stimulation session), then measured at the fifth stimulation session, and finally repeated at the follow-up session (within 7 days +/- 3 days after the final, fifth stimulation session)	Difference in shift of emotional bias between participants who receive five sessions of tsTMS (tACS + TMS) and participants who receive TMS alone (the two forms of tsTMS under study will be individually compared to TMS).
Primary	Frequency of adverse effects and tolerability	After each of the five stimulation sessions.	Total adverse effects score derived from the participant-completed adverse effects questionnaire administered after each stimulation session. The total score combines the frequency and severity of reported adverse effects.
Primary	Participant experience and acceptability	Follow-up visit within 7 days (±3 days) after the fifth stimulation session	Participant perceptions of the acceptability and experience of receiving tsTMS or TMS with sham tACS and of participating in the study, assessed through a semi-structured qualitative interview.
Secondary	Change in task-related theta-frequency brain oscillatory activity	Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5 min and 30 min post-stimulation) within the same session.	Change in task-related theta-frequency brain oscillatory activity following neuromodulation, measured using electroencephalography (EEG). The outcome will compare changes in the fronto-midline theta activity during a working memory task between participants receiving tsTMS and those receiving TMS with sham tACS.
Secondary	Change in Frontal Theta Power	Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.	Change in resting-state frontal theta power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Secondary	Change in Central Beta Power	Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.	Change in resting-state central beta power measured using electroencephalogram (EEG) during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Secondary	Change in Occipital Alpha Power	Stimulation Day 1. Pre-stimulation to post-stimulation (multiple timepoints at 5min and 30min post-stimulation) within the same session.	Change in resting-state occipital alpha power measured using EEG during eyes-open and eyes-closed conditions before and after neuromodulation. Changes following tsTMS will be compared with TMS with sham tACS.
Secondary	Change in Subjective Cognitive Difficulties (Perceived Deficits Questionnaire for Depression, 5-item version (PDQ-5-D))	Baseline and follow-up visit (within 7 days ±3 days after the fifth stimulation session).	Change in subjective cognitive difficulties from baseline to follow-up, assessed using the Perceived Deficits Questionnaire (PDQ-5-D). Changes following tsTMS will be compared with TMS with sham tACS. Total scores range from 0 to 20, with higher scores indicating greater perceived cognitive difficulties and lower scores indicating better subjective cognitive functioning.
Secondary	Change in Choice Reaction Time	Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).	Change in reaction time performance from baseline to follow-up, assessed using the THINC-it Choice Reaction Time task. Changes following tsTMS will be compared with TMS with sham tACS.
Secondary	Change in Digit Symbol Substitution Test (DSST) Performance	Baseline and follow-up visit (within 7 days ± 3 days after the fifth stimulation session).	Change in cognitive performance from baseline to follow-up, assessed using the Digit Symbol Substitution Test (DSST). Changes following tsTMS will be compared with TMS with sham tACS. The score is the total number of correct symbol-digit substitutions completed during the test period. Higher scores indicate better cognitive performance and faster processing speed, while lower scores indicate poorer performance.

1 to 10 of 17Source ClinicalTrials.gov

See all 17 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
40800403	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests2

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Choice Reaction Time	Secondary outcome	ConductCognition
Symbol Coding	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07879924

GET https://conductscience.org/api/trials/v1/NCT07879924/registered

API reference For AI assistants